^
Association details:
| Biomarker: | ER negative |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | albumin-bound paclitaxel (Bcl2 inhibitor, Tubulin inhibitor) + cyclophosphamide (Alkylating agent) + epirubicin (Topoisomerase II inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Neoadjuvant Epirubicin-Cyclophosphamide Therapy followed by Nab-Paclitaxel in Patients with Operable Breast Cancer-A Single-Center Phase Ⅱ Trial
Published date:
06/01/2022
Excerpt:
In patients with T1-3, N0-2, M0 breast cancer, 4 cycles of 260 mg/m2 nab-PTX were administered every 3 weeks after 4 cycles of EC therapy(100 mg/m2 of epirubicin and 600 mg/m2 of cyclophosphamide)as NAC. In HER2- positive patients, trastuzumab was used in combination with nab-PTX....Predictive factors for pCR were ER negativity and HER2 positivity....This study suggests the efficacy and safety of nab-PTX after EC therapy in Japanese patients with operable breast cancer.
